SGN-30 (Seattle genetics).
Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe.
Schnell
Roland
R
Department of Internal Medicine I, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. roland.schnell@uni-koeln.de
Borchmann
Peter
P
D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000175:diagnosis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D017730:Ki-1 Antigen / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D017730:Ki-1 Antigen; D011994:Recombinant Proteins